TY - JOUR T1 - Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and <em>In Vivo</em> Antitumor Activity JF - Anticancer Research JO - Anticancer Res SP - 2881 LP - 2885 VL - 33 IS - 7 AU - DAISUKE KUCHIIKE AU - YOSHIHIRO UTO AU - HIROTAKA MUKAI AU - NORIKO ISHIYAMA AU - CHIAKI ABE AU - DAICHI TANAKA AU - TOMOHITO KAWAI AU - KENTARO KUBO AU - MARTIN METTE AU - TOSHIO INUI AU - YOSHIO ENDO AU - HITOSHI HORI Y1 - 2013/07/01 UR - http://ar.iiarjournals.org/content/33/7/2881.abstract N2 - Background: The group-specific component protein-derived macrophage-activating factor (GcMAF) has various biological activities, such as macrophage activation and antitumor activity. Clinical trials of GcMAF have been carried out for metastatic breast cancer, prostate cancer, and metastatic colorectal cancer. In this study, despite the complicated purification process of GcMAF, we used enzymatically-treated human serum containing GcMAF with a considerable macrophage-stimulating activity and antitumor activity. Results: We detected GcMAF in degalactosylated/desialylated human serum by western blotting using an anti-human Gc globulin antibody, and Helix pomatia agglutinin lectin. We also found that GcMAF-containing human serum significantly enhanced the phagocytic activity of mouse peritoneal macrophages and extended the survival time of mice bearing Ehrlich ascites tumors. Conclusion: We demonstrated that GcMAF-containing human serum can be used as a potential macrophage activator for cancer immunotherapy. ER -